Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation
Abstract Clinical responses with chimeric antigen receptor (CAR) T cells are encouraging, but primary resistance and relapse after therapy prevent durable remission in many patients with cancer, with apoptosis resistance in cancer cells that limits killing by CAR T cells being a potential cause. Her...
Saved in:
| Main Authors: | Thomas Kimman, Marta Cuenca, Ralph G. Tieland, Dedeke Rockx-Brouwer, Jasmijn Janssen, Benjamin Motais, Anne Slomp, Corine Pleijte, Sabine Heijhuurs, Angelo D. Meringa, Wendy Boschloo, Douwe MT Bosma, Sanne Kroos, Vania lo Presti, Joost P. G. Sluijter, Stefan Nierkens, Niels Bovenschen, Jürgen Kuball, Alain van Mil, Monique C. Minnema, Zsolt Sebestyén, Victor Peperzak |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-59818-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Expression of TNF-α, April and BCMA in Behcet’s Disease
by: Olfat G. Shaker, et al.
Published: (2014-01-01) -
BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma
by: Chengwei Jin, et al.
Published: (2025-12-01) -
Targeting BCMA in multiple myeloma: designs, challenges, and future directions
by: Yi Hu, et al.
Published: (2025-02-01) -
Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma
by: Joshua N. Gustine, et al.
Published: (2025-06-01) -
The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma
by: Adrian Schmidt
Published: (2023-10-01)